logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11131677 B1

PDFFull Text
Date of Patent:
Sep. 28, 2021

Filed:

Apr. 10, 2019

Methods for treating testosterone deficiency in men and methods for precise dosing of ugt2b17 substrate drugs

Applicant:

University of Washington, Seattle, WA (US);

Inventors:

Bhagwat Prasad, Seattle, WA (US);

Abdul Basit, Seattle, WA (US);

Haeyoung Zhang, Seattle, WA (US);

John K. Amory, Seattle, WA (US);

Assignee:

University of Washington, Seattle, WA (US);

Attorney:

Christensen O'Connor Johnson Kindness PLLC

Primary Examiner:

Theodore R Howell

Int. Cl.
CPC ...
G01N 33/74 (2006.01); A61K 31/5685 (2006.01); A61K 31/192 (2006.01); A61K 31/196 (2006.01); A61K 31/506 (2006.01); A61K 31/167 (2006.01); A61P 5/26 (2006.01); G01N 33/573 (2006.01); A61K 31/4365 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/743 (2013.01); A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 31/196 (2013.01); A61K 31/4365 (2013.01); A61K 31/506 (2013.01); A61K 31/5685 (2013.01); A61P 5/26 (2018.01); G01N 33/573 (2013.01); A61K 9/0053 (2013.01); C12Y 204/01017 (2013.01); G01N 2333/91102 (2013.01); G01N 2800/52 (2013.01);
Abstract

Treatment of testosterone deficiency in men by a precision medicine approach using a biomarker of activity of UGT2B17 that is involved in testosterone urinary elimination. By inhibiting UGT2B17, alone or in combination with administration of testosterone, testosterone deficiency in men can be treatable. Further, a method of dose selection for precise dosing of UGT2B17 substrate drugs is provided. Additionally, methods for safe dosing of pharmaceutical agents that undergo UGT2B17-mediated acyl glucuronidation are provided.

Find Patent Forward Citations

Loading…